The work by Bove et al. [16] on xanthine oxidase inhibitors provides compelling evidence for the therapeutic potential of targeting uric acid pathways in hypertension management, particularly in cases resistant to conventional treatments. The gene discussed is XDH; the disease is hypertensive disorder.